Article

HEMATOLOGICAL ADVERSE EVENTS ON THE BACKGROUND OF ANTIVIRAL THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C

Ismatova M.NBukhara State Medical Institute, Bukhara, UzbekistanNurullaeva D.F.Bukhara State Medical Institute, Bukhara, Uzbekistan

Zenodo (CERN European Organization for Nuclear Research)repository2022en

ABI

Abstract

Abstract. Currently, the main etiotropic method of treating chronic hepatitis C is combination therapy with standard interferon-a (IFN-a) or pegylated interferon-a (PIFN-a) in combination with ribavirin. Despite significant advances in AVT in CHC patients, adverse events may occur during treatment, which force either to reduce the dosage of drugs or stop treatment altogether.

Topics

Hermeneutics and Narrative Identity Aging, Elder Care, and Social Issues Health, Medicine and Society

Identifiers

DOI: 10.5281/zenodo.7331149

Citations and references

Cited by 00 references

Metrics — AkademScholar